Phacoemulsification with PMMA IOL — Cost, Top Hospitals & Success Rates | MyMedicPlus

Polymethylmethacrylate (PMMA), the material widely known under trade names such as Perspex, Plexiglas, and Lucite, has the distinction of being the world's first successful intraocular lens material. Sir Harold Ridley implanted the inaugural posterior chamber IOL in 1949 at St Thomas' Hospital, London, after observing that PMMA fragments from shattered aircraft cockpit canopies were well tolerated within the eyes of RAF pilots — a pivotal observation that launched the modern era of cataract surgery.

PMMA is a rigid, transparent polymer with a refractive index of 1.49 and exceptional optical clarity. It is chemically inert within the eye, dimensionally stable over decades, and demonstrates excellent biocompatibility. Because PMMA cannot be folded, lenses made from this material must be implanted through a sufficiently large incision to accommodate the full optic diameter — typically 5.5–6.5 mm — which must then be sutured closed.

In developed countries, PMMA IOLs have been largely supplanted by foldable acrylic and silicone IOLs that permit sutureless micro-incision surgery. However, PMMA remains in widespread clinical use globally for several important reasons: its dramatically lower cost (often one-tenth the price of a premium foldable IOL), its proven multi-decade durability, the absence of materials-related issues such as glistening or PCO promotion found in some polymer formulations, and its continued role as the lens of choice for manual small-incision cataract surgery (MSICS) — the high-volume technique dominant in South Asia and Sub-Saharan Africa.

When performed in combination with phacoemulsification (rather than the more traditional MSICS approach), a PMMA IOL requires a scleral tunnel extension of the phaco incision from the standard 2.2–2.75 mm to 5.5–6 mm to permit rigid lens insertion. This hybrid technique preserves the benefits of phaco nucleus removal while using a cost-effective PMMA lens.

Phacoemulsification with PMMA IOL treats the full spectrum of cataract presentations:

Age-Related (Senile) Cataract

Nuclear sclerosis, posterior subcapsular cataract, and cortical cataract causing visually significant reduction in acuity, contrast sensitivity, or glare disability.

Mature and Hypermature Cataract

Dense brunescent (brown/black) cataracts that require very high phacoemulsification energy — or conversion to manual expression — particularly benefit from PMMA as the rigid lens is unaffected by the additional phaco energy used to emulsify hard nuclei.

Traumatic Cataract

Post-injury lens opacification, sometimes requiring large incision surgery if zonular disruption or lens fragmentation complicates the procedure. PMMA can be placed in the ciliary sulcus if the posterior capsule is damaged.

Paediatric Cataract

In children under 5 years, IOL implantation is sometimes deferred in favour of aphakic spectacle or contact lens correction. When IOL implantation is performed in older children, PMMA lenses have a well-documented tolerance profile in the paediatric eye, though modern foldable IOLs are increasingly preferred.

Secondary IOL Implantation

In aphakic eyes without capsular support, PMMA IOLs can be sutured to the sclera (scleral-fixated IOL) or iris (iris-claw IOL — the Artisan/Veriflex design, also made of PMMA) when foldable in-the-bag implantation is not feasible.

Candidacy for phaco with PMMA IOL should be considered in the following scenarios:

Cost-Driven Candidacy

• Patients in low- and middle-income countries seeking effective cataract surgery at maximum affordability
• Bilateral simultaneous cataract patients where total IOL cost is a material constraint
• Patients with basic insurance covering only conventional (non-premium) lens types

Clinical Candidacy

• Patients with prior vitreoretinal surgery requiring silicone oil tamponade — PMMA is unaffected by silicone oil (unlike some hydrophobic acrylic IOLs which suffer from oil droplet adhesion)
• Patients with complicated intraoperative scenarios requiring in-the-sulcus placement — PMMA sulcus-fixated IOLs have a proven track record
• Eyes requiring scleral-fixated secondary IOL where suturing capabilities are preferred with a rigid optic
• Cases with poor capsular support where a 3-piece PMMA design with large PMMA haptics offers mechanical stability

Pre-operative Assessment

Pre-operative workup is identical to standard phacoemulsification: biometry for IOL power calculation, slit-lamp assessment of lens opacity and anterior segment, IOP measurement, and posterior segment evaluation by fundoscopy or OCT. Surgeons should be aware that IOL power tables and constants for PMMA lenses differ from acrylic formulations, and appropriate A-constants must be used for accurate power calculation.

Relative Contraindications to PMMA IOL

• Patient requesting toric (astigmatism-correcting) lens — toric PMMA IOLs are not widely available; a toric foldable IOL would be preferred
• Patient requesting multifocal or EDOF correction — multifocal PMMA IOLs are not standard; premium foldable IOLs are required
• Very small pupil with limited surgical access for the larger PMMA incision

Phacoemulsification with PMMA IOL combines ultrasonic nucleus removal with rigid lens insertion via an enlarged incision:

Operative Steps

1. Anaesthesia: Peribulbar or sub-Tenon block is standard; the larger incision and suturing require predictable akinesia. Topical anaesthesia alone may be insufficient for comfortable lid speculum retraction with a larger wound.
2. Incision: A scleral tunnel of 5.5–6.5 mm is constructed (or the phaco wound is enlarged at lens insertion stage). The scleral tunnel architecture (square tunnel entry into clear cornea) provides wound stability.
3. Capsulorhexis: Continuous curvilinear capsulorhexis (CCC) of 5–5.5 mm diameter, centred on the visual axis.
4. Phacoemulsification: Nucleus emulsification using standard divide-and-conquer or chopping techniques. Cortex aspiration with irrigation-aspiration handpiece.
5. IOL insertion: The PMMA lens is inserted directly into the capsular bag (if intact) using implantation forceps. No folding or injector is required. The rigid haptics are manipulated with a lens hook to position the lens correctly.
6. Wound closure: The scleral tunnel is closed with 1–3 interrupted 10-0 nylon sutures. Suture tension controls post-operative astigmatism and is adjusted to minimise induced cylinder.

PMMA IOL Designs

• One-piece PMMA: Optic and haptics moulded from a single piece of PMMA. Robust design used in most standard posterior chamber applications.
• Three-piece PMMA: PMMA optic with PMMA, prolene, or blue PMMA haptics. The three-piece design allows sulcus placement when capsular support is compromised.
• Iris-claw (Artisan) PMMA: A specific design by Ophtec (Netherlands) that fixates to the iris mid-periphery — used for secondary IOL implantation in aphakic eyes without capsular or zonular support.

PMMA IOL Power Range

Available from -10 D to +35 D in most standard ranges, with custom manufacturing possible for extreme eyes. A-constant for standard posterior chamber PMMA is typically 118.0–118.4 (IOLMaster).

PMMA IOLs offer a distinct set of advantages that continue to make them relevant in global cataract practice:

• Proven 60+ year track record: No other IOL material has Ridley's original 1949 implantation as its foundational clinical evidence. Multi-decade follow-up studies confirm that PMMA in the eye is biologically stable, does not degrade, and maintains optical clarity for the patient's lifetime.
• Cost-effectiveness: PMMA IOLs cost a fraction of modern foldable acrylic lenses — often $5–$20 per lens versus $80–$250 for foldable options. This cost difference is critical in enabling universal access to vision restoration in low-resource settings.
• No material-related glistening: The polymer crystallisation phenomenon (glistening) that affects first-generation AcrySof lenses does not occur with PMMA, ensuring permanent optical clarity without material-related optical degradation.
• Silicone oil compatibility: PMMA is fully compatible with silicone oil vitreoretinal procedures. Oil droplets do not adhere to PMMA surfaces (as they can with some hydrophobic acrylic IOLs), making PMMA the preferred lens in eyes at high risk of requiring oil tamponade.
• Stability in the sulcus: Three-piece PMMA lenses with rigid PMMA or prolene haptics maintain stable centration in the ciliary sulcus when in-the-bag implantation is not possible — a significant advantage in complicated cases.
• Toughness: PMMA is mechanically robust and resistant to physical deformation or cracking under physiological conditions.

The trade-offs of using a rigid PMMA IOL versus a foldable lens should be clearly understood:

Larger Incision and Suture-Related Issues

• Higher surgically induced astigmatism (SIA): The 5.5–6.5 mm wound introduces significantly more post-operative astigmatism (typically 0.5–1.5 D) than the self-sealing 2.2 mm microincision of standard phacoemulsification.
• Suture-related complications: Nylon sutures can loosen, break, or cheese-wire through the sclera over months to years, causing late-onset irregular astigmatism. Sutures require monitoring and elective removal at 6–12 months in some cases.
• Slower visual recovery: Astigmatism stabilises fully as sutures are removed and wound architecture remodels — typically 8–12 weeks versus 4–6 weeks for micro-incision surgery.

Surgical Limitations

• No toric correction available in standard PMMA IOLs — pre-existing corneal astigmatism cannot be addressed within the IOL design
• No multifocal or EDOF optics — reading glasses will always be required
• PMMA is stiffer, making positioning in a small capsular bag more challenging in small eyes or paediatric cases

Standard Phacoemulsification Risks (applicable to all IOL types)

• Posterior capsule rupture (0.5–2%)
• Endophthalmitis (<0.05%)
• Cystoid macular oedema (1–2%)
• Posterior capsule opacification (PCO rates are somewhat higher with PMMA — up to 15–20% at 5 years — than with modern hydrophobic sharp-edge lenses, as PMMA optic edges are less efficient at inhibiting lens epithelial cell migration)

Recovery following phaco with PMMA IOL is slightly longer than with microincision foldable IOL surgery due to the sutured larger incision:

Day 0–1

An eye pad and shield are applied post-operatively. Topical antibiotic and steroid drops are initiated. Vision may be blurred due to residual astigmatism from suture tension. Day 1 review assesses wound integrity, IOP, and anterior chamber reaction.

Weeks 1–4

Topical drops continue for 4 weeks. Patients are advised against heavy lifting, swimming, and eye rubbing. Vision improves progressively as corneal oedema and inflammation resolve, but the full refractive endpoint is not stable until sutures are removed or remodelled.

Months 1–3

Suture management is the key post-operative consideration. Some surgeons leave sutures permanently; others routinely remove them at 6–12 weeks. Selective suture removal under slit-lamp guidance can neutralise residual suture-induced with-the-rule or against-the-rule astigmatism, allowing fine-tuning of the refraction before spectacle prescription. A stable spectacle correction is issued once the refraction is confirmed stable on two consecutive visits at least 2 weeks apart.

Long-term Monitoring

Annual ophthalmic review monitors for PCO, IOP, and posterior segment changes. PCO rates with PMMA are higher than with modern hydrophobic acrylic IOLs; patients should be counselled that an Nd:YAG capsulotomy may be needed at some point (10–20% at 5 years). Nd:YAG is a brief, painless outpatient laser procedure requiring no anaesthesia.

The principal appeal of PMMA IOL for many patients is economic. Total procedural cost is meaningfully lower than foldable IOL surgery, primarily driven by lens cost and (in high-volume settings) technique efficiency:

IOL Cost Differential

• PMMA IOL: $5–$30 per lens (manufacturing cost in volume)
• Standard foldable acrylic IOL: $60–$250 per lens
• Premium foldable (toric, multifocal): $250–$1,200+ per lens

Approximate Total Cost per Eye (USD, phaco + PMMA IOL)

India's network of high-volume eye hospitals (Aravind Eye Care, LV Prasad Eye Institute, Sankara Nethralaya) perform phaco with PMMA IOL at extremely low costs with outcomes comparable to leading Western centres, supported by robust quality-control programmes and telemedicine follow-up infrastructure.

Patients choosing cataract surgery have several IOL material alternatives to PMMA:

• Hydrophobic acrylic foldable IOL (e.g., AcrySof IQ, Hoya Vivinex): The current global gold standard. Requires a 2.2–2.75 mm sutureless incision. Lower PCO rates, faster recovery, and toric/multifocal designs available. Higher IOL cost.
• Hydrophilic (hydrogel) acrylic foldable IOL (e.g., Rayner C-flex, Contamac): Foldable, sutureless microincision, highly biocompatible. Slightly higher PCO rates than hydrophobic. Popular in UK and continental Europe. Not suitable for silicone oil cases.
• Silicone foldable IOL: Earliest foldable material with excellent optics. Now used infrequently due to silicone oil incompatibility. Rarely implanted in new surgeries.
• Manual small-incision cataract surgery (MSICS) + PMMA: An alternative to phacoemulsification using a self-sealing scleral tunnel without ultrasound phaco energy. Larger incision but no sutures required (self-sealing tunnel). Highly cost-effective, used widely in South Asia and Africa. Outcomes equivalent to phaco in randomised trials (ISCRS studies).
• Premium multifocal/EDOF IOLs (foldable only): If spectacle independence from both near and distance is the goal, premium foldable multifocal (Alcon PanOptix, AMO Tecnis Symfony) or EDOF (Alcon Vivity) lenses are alternatives — albeit at significantly higher cost and with trade-offs of photic phenomena (halos, glare).